Kura Oncology vs Spero Therapeutics
Kura Oncology reported revenue of $68 million in fiscal 2025, about the same as Spero Therapeutics' $67 million in fiscal 2025. Kura Oncology's revenue grew 25.2% in its latest year, and Spero Therapeutics' grew 39.2%. Kura Oncology had an operating margin of -449.9%, against 9.4% at Spero Therapeutics.
Side by side
| Kura Oncology | Spero Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $68M | $67M |
| Revenue growth | 25.2% | 39.2% |
| Revenue growth a year, last 5 years | — | 48.3% |
| Gross margin | — | — |
| Operating margin | −449.9% | 9.4% |
| Net margin | −412.9% | 12.8% |
| Free cash flow | −$71M | — |
| Free cash flow margin | −104.8% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.8% | 9.3% |
| Last close | $7.35 | $0.83 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $3.9 million, sold $4.0 million | sold $456,601 |
| Piotroski F-score | 3 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Kura OncologySpero Therapeutics
Operating margin
Percent of revenue
Kura OncologySpero Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kura OncologySpero Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kura Oncology and Spero Therapeutics pages.